The new naphtha cavern has recently been commissioned in Porvoo, Finland. With this project, Borealis will now be able to source and store naphtha from the global market in a cost-efficient manner. The cavern is also expected to store renewable naphtha which proves useful for the production of renewable polyolefins.

With the hefty investment, Lonza aims to expand its overall capsule production capacity within Capsules and Health Ingredients (CHI) division’s Capsugel portfolio by 30 billion capsules every year. The investment is expected to increase CHI's current capsule production capacity by 15 %.

Roche has teamed up with Atea Pharmaceuticals to jointly develop AT-527, an orally administered direct-acting antiviral currently in Phase 2 clinical trials. If approved, AT-527 will be the first novel oral antiviral to treat Covid-19 patients.

With the acquisition of Medipac, a Swedish manufacturer of tube filling machines, Romaco will become the only supplier in the world to offer complete line configurations for all effervescents. The contracts just were signed.

LG Chem claims that the new biodegradable material is the only biodegradable material with 100 % bio contents and is also the only material which offers mechanical properties equivalent to polypropylene.

Under the MOU signed between BASF New Business (BNB) and the South Korean based firm G-Philos, BNB will supply Nas batteries to G-Philos till 2022 as well as support the firm in the development of the Power Conversion Systems business for Nas batteries.

Valagro is one of the leading biologicals company and with this takeover the Syngenta Group aims to provide farmers with more complementary product and technology choices. The acquisition will also strengthen the company in the biologicals market which is expected to double in size over the next five years.

Reig Jofre has entrusted Ima Life with the installation of its new line of sterile freeze-dried products, the largest and most modern in Spain. A complete, versatile, fully automated line designed to adapt to the manufacture of different products with the highest quality and in compliance with the new Annex 1 of the GMPs.

Cefic’s latest data has revealed that chemical output from June reported 2.9 % output growth compared to May of the same year however, it is still about 9 % below the pre-crisis level i.e. June compared to Feb of 2020.

Under the terms of the licensing agreement, Atum’s Leap-In Transposase technology will be integrated into Rentschler’s in-house process to complement its existing cell line development offering. The technology platform is ideal for the production of standard antibodies as well as complex, multi-chain therapeutic proteins.